William R. Wilcox
William R. Wilcox has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Pavel Krejci
Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
4 shared publications Ralph S. Lachman
Department of Radiology, UCLA School of Medicine, Los Angeles, California
4 shared publications- Dominique Paul Germain
Division of Medical Genetics, University of Versailles–St Quentin en Yvelines (UVSQ), Paris–Saclay University, Montigny, France
3 shared publications Alois Kozubik
Institute of Experimental Biology, Masaryk University, 61137 Brno, Czech Republic
2 shared publications- Clair A. Francomano
Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland
2 shared publications - David G. Warnock
University of Alabama
2 shared publications
Latest Publications
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S55
Risk factors for severe clinical events and the incidence of these events in male and female patients with Fabry disease treated with agalsidase beta
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S55
Risk factors for severe clinical events and the incidence of these events in male and female patients with Fabry disease treated with agalsidase beta
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S45-S46
A 10-year study documenting the long-term effectiveness of agalsidase-beta treatment in 52 adult patients with classic Fabry disease
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S45-S46
A 10-year study documenting the long-term effectiveness of agalsidase-beta treatment in 52 adult patients with classic Fabry disease
- 6 July 2013
- Published by Wiley in Clinical Genetics
- Vol. 86 (1) , 74-84
Phenotype–genotype correlations in patients with Marinesco–Sjögren syndrome
Marinesco–Sjögren syndrome (MSS; MIM 248800) is an autosomal recessive disorder characterized by congenital cerebellar ataxia, early cataracts, developmental delay, myopathy and short stature. Alterations in the gene SIL1 cause MSS in some patients with typical findings. In this study, molecular investigations including sequencing of the SIL1 gene, western blotting and microscopic investigations in fibroblast cultures were carried out in a cohort of 15 patients from 14 unrelated families, including the large, inbred family reported by Superneau et al., having the clinical features of MSS to provide insights into the pathophysiology of the disorder. A total of seven different mutations were found in eight of the patients from seven families. The mutations caused loss of the BIP-associated protein (BAP) protein in four patients by western blot. Novel clinical features such as dental abnormalities, iris coloboma, eczema and hormonal abnormalities were noticed in some patients, but there was no clear way to distinguish those with and without SIL1 mutations. Cultured fibroblasts contained numerous cytoplasmic inclusion bodies, similar to those identified in the brain of the whoozy mouse in five unrelated patients, three with and two without SIL1 mutations, suggesting some SIL1 negative patients share a common cellular pathogenesis with those who are SIL1 positive.
- 6 July 2013
- Published by Wiley in Clinical Genetics
- Vol. 86 (1) , 74-84
Phenotype–genotype correlations in patients with Marinesco–Sjögren syndrome
Marinesco–Sjögren syndrome (MSS; MIM 248800) is an autosomal recessive disorder characterized by congenital cerebellar ataxia, early cataracts, developmental delay, myopathy and short stature. Alterations in the gene SIL1 cause MSS in some patients with typical findings. In this study, molecular investigations including sequencing of the SIL1 gene, western blotting and microscopic investigations in fibroblast cultures were carried out in a cohort of 15 patients from 14 unrelated families, including the large, inbred family reported by Superneau et al., having the clinical features of MSS to provide insights into the pathophysiology of the disorder. A total of seven different mutations were found in eight of the patients from seven families. The mutations caused loss of the BIP-associated protein (BAP) protein in four patients by western blot. Novel clinical features such as dental abnormalities, iris coloboma, eczema and hormonal abnormalities were noticed in some patients, but there was no clear way to distinguish those with and without SIL1 mutations. Cultured fibroblasts contained numerous cytoplasmic inclusion bodies, similar to those identified in the brain of the whoozy mouse in five unrelated patients, three with and two without SIL1 mutations, suggesting some SIL1 negative patients share a common cellular pathogenesis with those who are SIL1 positive.
- 16 June 2009
- Published by Hindawi Limited in Human Mutation
- Vol. 30 (9) , 1245-1255
Molecular pathology of the fibroblast growth factor family
The human fibroblast growth factor (FGF) family contains 22 proteins that regulate a plethora of physiological processes in both developing and adult organism. The mutations in the FGF genes were not known to play role in human disease until the year 2000, when mutations in FGF23 were found to cause hypophosphatemic rickets. Nine years later, seven FGFs have been associated with human disorders. These include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo‐auriculo‐dento‐digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets. The heterogeneity in the functional consequences of FGF mutations, the modes of inheritance, pattern of involved tissues/organs, and effects in different developmental stages provide fascinating insights into the physiology of the FGF signaling system. We review the current knowledge about the molecular pathology of the FGF family. Hum Mutat 30:1–11, 2009.
- 16 June 2009
- Published by Hindawi Limited in Human Mutation
- Vol. 30 (9) , 1245-1255
Molecular pathology of the fibroblast growth factor family
The human fibroblast growth factor (FGF) family contains 22 proteins that regulate a plethora of physiological processes in both developing and adult organism. The mutations in the FGF genes were not known to play role in human disease until the year 2000, when mutations in FGF23 were found to cause hypophosphatemic rickets. Nine years later, seven FGFs have been associated with human disorders. These include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo‐auriculo‐dento‐digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets. The heterogeneity in the functional consequences of FGF mutations, the modes of inheritance, pattern of involved tissues/organs, and effects in different developmental stages provide fascinating insights into the physiology of the FGF signaling system. We review the current knowledge about the molecular pathology of the FGF family. Hum Mutat 30:1–11, 2009.
- Top Cited Papers
- 1 February 2008
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 93 (2) , 112-128
Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
- 1 February 2008
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 93 (2) , 112-128
Top Cited PapersFemales with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
- 30 July 2005
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 136A (3) , 233-241
Spondylo-mega-epiphyseal dysplasia with prominent upper limb mesomelia, punctate calcifications, and deafness
We report on a previously undescribed form of skeletal dysplasia with rhizomelic, acromelic, and prominent mesomelic shortening, distal ulnar epiphyseal and pubic punctate calcifications (stippling), mega‐epiphyses, platyspondyly, anterior beaking of the vertebrae, and sensorineural hearing loss. We compare this case to the other reported forms of skeletal dysplasias, particularly the mesomelic, acromesomelic, and mega‐epiphyseal disorders.
- 30 July 2005
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 136A (3) , 233-241
Spondylo-mega-epiphyseal dysplasia with prominent upper limb mesomelia, punctate calcifications, and deafness
We report on a previously undescribed form of skeletal dysplasia with rhizomelic, acromelic, and prominent mesomelic shortening, distal ulnar epiphyseal and pubic punctate calcifications (stippling), mega‐epiphyses, platyspondyly, anterior beaking of the vertebrae, and sensorineural hearing loss. We compare this case to the other reported forms of skeletal dysplasias, particularly the mesomelic, acromesomelic, and mega‐epiphyseal disorders.
- 7 March 2005
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 135A (1) , 110-112
Differentiating campomelic dysplasia from Cumming syndrome
- 7 March 2005
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 135A (1) , 110-112
Differentiating campomelic dysplasia from Cumming syndrome
- 24 August 2004
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 130A (1) , 96-97
Mutations in the EVC1 gene are not a common finding in the Ellis‐van Creveld and short rib‐polydactyly type III syndromes
- 24 August 2004
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 130A (1) , 96-97
Mutations in the EVC1 gene are not a common finding in the Ellis‐van Creveld and short rib‐polydactyly type III syndromes